A Multicenter, Single- Arm Study of Quantitative Assessment of Walking (Squawk) With the Canary canturioTM te (CTE) Tibial Extension

Sponsor
Canary Medical (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05693818
Collaborator
(none)
88
1
3.9
22.3

Study Details

Study Description

Brief Summary

The objective of this prospective study is to demonstrate accuracy of a limp detection model using a healthcare provider assessment as the non-reference standard.

Condition or Disease Intervention/Treatment Phase
  • Other: Clinical Limping Evalution

Detailed Description

The primary endpoint of the study is limp severity at the 4-6 week office visit. At 4-6 weeks (+/- 3 days) post-surgery, the healthcare team will assess the patient's limp severity by visual observation on a 3-point Likert scale (0=No limp, 1=Mild/Moderate or 2=Severe).

Study Design

Study Type:
Observational
Anticipated Enrollment :
88 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Multicenter, Single- Arm Study of Quantitative Assessment of Walking (Squawk) With the Canary canturioTM te (CTE) Tibial Extension
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
May 1, 2023

Arms and Interventions

Arm Intervention/Treatment
PersonaIQ

Patients indicated for a PersonaIQ total knee arthroplasty

Other: Clinical Limping Evalution
Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp). If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided.
Other Names:
  • Limp Detection
  • Outcome Measures

    Primary Outcome Measures

    1. Limp Severity [4-6 wks+3 days weeks post TKA]

      The primary endpoint of the study is limp severity at the 4-6 week office visit. At 4-6 weeks (+/- 3 days) post-surgery, the healthcare team will assess the patient's limp severity by visual observation on a 3-point Likert scale (0=No limp, 1=Mild/Moderate or 2=Severe).

    Secondary Outcome Measures

    1. Test-retest reliability of the Canary Medical Limping Model (CMLM) score [4-6 wks+3 days weeks post TKA]

      Test-retest reliability of the CMLM score from day-to-day and week-to-week. (Specific days and weeks will be provided in the Statistical Analysis Plan.)

    2. Positive Percent Agreement (PPA) of the CMLM with the healthcare team's assessment [4-6 wks+3 days weeks post TKA]

    3. Negative Percent Agreement (NPA) of the CMLM with the healthcare team's assessment [4-6 wks+3 days weeks post TKA]

    4. Knee Range of Motion [4-6 wks+3 days weeks post TKA]

      ROM will be measured by a goniometer

    5. Numeric Pain Rating Scale [4-6 wks+3 days weeks post TKA]

      Subjective Pain Measurement

    6. KOOS Jr [4-6 wks+3 days weeks post TKA]

      Patient Reported outcome

    7. Limping Self Evaluation [4-6 wks+3 days weeks post TKA]

      Study participants will be asked the following question, "During the past week, have you been limping when walking, because of your knee?" The following answers will be allowed: Rarely / never Sometimes or just at first, after sitting for a long time Often, not just at first Most of the time All of the time

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • • Patient must be 18 years of age or older

    • Independent of study participation, patient is indicated for a commercially available PIQ TKA implant in accordance with product labeling

    • Patient must be willing and able to complete the protocol required follow-up

    • Patient has participated in the study-related informed consent process

    • Patient is willing and able to provide written Informed Consent by signing and dating the IRB approved informed consent

    Exclusion Criteria:
    • • Simultaneous bilateral TKA

    • Staged bilateral TKA less than 6 months from indexed procedure

    • Patient is a current alcohol or drug abuser

    • Patient is known to be pregnant, breastfeeding, or considered a member of a protected class (e.g., prisoner, mentally incompetent, etc.)

    • Patient has a psychiatric illness or cognitive deficit that will not allow proper informed consent and participation in follow-up program

    • Patient with mental or neurologic conditions who are unwilling or incapable of following postoperative care instructions

    • Patient with Neuropathic Arthropathy

    • Patient with any loss of musculature or neuromuscular disease that compromises the affected limb

    • Patients with known symptomatic foot, hip or spinal injuries and/or conditions that could affect gait

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Carolina Orthopaedic & Neurosurgical Associates Spartanburg South Carolina United States 29303

    Sponsors and Collaborators

    • Canary Medical

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Canary Medical
    ClinicalTrials.gov Identifier:
    NCT05693818
    Other Study ID Numbers:
    • POS-CTE-003
    First Posted:
    Jan 23, 2023
    Last Update Posted:
    Jan 23, 2023
    Last Verified:
    Jan 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Canary Medical
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 23, 2023